Skip to content

Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 16 October 2026.

Announcements

308

Total raised

£4.1B

disclosed amounts

This month

£27.8M

raised so far

Series B
£20.0M

The oversubscribed round included backing from Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence.

"This substantial investment round demonstrates continued confidence in the progress of our technical development and its potential to revolutionise the accessibility of gene synthesis. Evonetix is in a very exciting phase, having recently opened our early access program. This investment will support us as we execute on our commercial strategy to put benchtop gene synthesis in the hands of users."
— Colin McCracken, Chief Executive Officer
Pre-Seed
£1.2M

The pre-seed round was led by Science Angel Syndicate and Fink Family Office to develop cold chain-free vaccine technology.

"Our goal are to make the transportation of vaccines and other life-saving biological materials more efficient and cost-effective while also reducing the carbon footprint of this critical supply chain. We are thrilled to have the support of our investors as we work towards this mission."
— Asel Sartbaeva, CEO
Series A
£7.5M

The Scottish National Investment Bank led the Series A round to accelerate clinical validation and regulatory submission of the company's respiratory monitoring platform.

"We are delighted to close this round and thank both our existing investors and the Scottish National Investment Bank for their support,"
— Bruce Henderson, CEO
Seed
£3.0M

The funding round was led by Eka Ventures and will support international studies and product development.

"Existing data suggests that current approaches fall short at accurately detecting and localizing the deadliest cancers that desperately need to benefit from a blood test. At OXcan, we are using state-of-art and unbiased high-throughput proteomics approaches to examine hundreds and thousands of proteins in blood samples from largest studies of their kind for the first time. Combined with proprietary and tailored machine learning approaches, the results are products that fully integrate with existing care pathways and can detect and localize the deadliest cancers with unprecedented sensitivity and specificity."
— Peter Liu, CEO